Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target.

MLA

Sparrow, Miles P. “Adalimumab in Ulcerative Colitis - Efficacy, Safety and Optimization in the Era of Treat-to Target.” Expert Opinion on Biological Therapy, vol. 17, no. 5, May 2017, pp. 613–21. EBSCOhost, https://doi.org/10.1080/14712598.2017.1309390.

APA

Sparrow, M. P. (2017). Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target. Expert Opinion on Biological Therapy, 17(5), 613–621. https://doi.org/10.1080/14712598.2017.1309390

Chicago

Sparrow, Miles P. 2017. “Adalimumab in Ulcerative Colitis - Efficacy, Safety and Optimization in the Era of Treat-to Target.” Expert Opinion on Biological Therapy 17 (5): 613–21. doi:10.1080/14712598.2017.1309390.